Myriad Genetics, Inc.
NASDAQ:MYGNMedical - Diagnostics & Research
+$0.14 today
- Market cap
- $530.45M
- Beta
- 1.64
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$4.27
Volume 1.26M
Average 1.81M
MYGN Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Myriad Genetics, Inc.NASDAQ: MYGN
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 35.5% from a year ago
Cash & equivalents stood at $124.4M at the end of Q1 FY2026, up 35.5% from a year earlier and down 16.8% from the prior quarter. Over 3 fiscal years it compounded at +38.0% a year.
Context
- Cash & equivalents amounted to 18.5% of total assets at the end of Q1 FY2026, up 9.3 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +35.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 149.6M USD
- Year-over-year change
- +46.1%
- 4-year CAGR
- -12.8%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 149.6M | +46.1% |
| FY2024 | 2024-12-31 | 102.4M | -22.5% |
| FY2023 | 2023-12-31 | 132.1M | +132.2% |
| FY2022 | 2022-12-31 | 56.9M | -78.0% |
| FY2021 | 2021-12-31 | 258.4M | — |
Cash & Equivalents vs competitors
How MYGN compares with its peers on the latest reported figures
- MYGN's Mar 2026 cash & equivalents of $124.4M is the 7th highest of the 10 companies compared; the peer median is $299.52M.
- Its year-over-year change of +35.5% is the 4th highest of 10, against a peer median of +4.7%.
- Cash & equivalents amounts to 18.5% of total assets for MYGN, versus a peer median of 22.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.09B | +9.1% | +32.2% | 41.1% | |
| Sep 2026 | $1.03B | +77.0% | +38.7% | 54.5% | |
| Jun 2026 | $768.5M | +4.7% | +4.7% | 13.0% | |
BLLNBillionToOne, Inc. | Jun 2026 | $548.63M | +190.3% | — | 75.2% |
| Jun 2026 | $299.52M | +36.5% | +33.0% | 20.2% | |
| Jun 2026 | $145.54M | -5.9% | -15.4% | 10.8% | |
| Mar 2026 | $124.4M | +35.5% | +38.0% | 18.5% | |
| Mar 2026 | $73.59M | +3.7% | +11.7% | 22.6% | |
IMDXInsight Molecular Diagnostics Inc. | Mar 2026 | $28.2M | -9.1% | -16.6% | 69.8% |
| Mar 2026 | $23.4M | -65.2% | -14.2% | 2.0% | |
| Peer median (excluding MYGN) | $299.52M | +4.7% | +8.2% | 22.6% | |
Competitors are the stored peer set for MYGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 258.4M | 56.9M | 132.1M | 102.4M | 149.6M |
| Short-term Investments | 81.4M | 58M | 8.8M | 0 | 0 |
| Net Receivables | 91.3M | 101.6M | 114.3M | 121.2M | 115.3M |
| Inventory | 15.3M | 20.1M | 22M | 27.5M | 30.6M |
| Other Current Assets | 38.4M | 20.4M | 19.4M | 30.5M | 37.1M |
| Total Current Assets | 484.8M | 274.6M | 313.6M | 298M | 332.6M |
| Property, Plant & Equipment (Net) | 125.3M | 187.3M | 180.6M | 172.4M | 163.4M |
| Goodwill | 239.2M | 286.8M | 287.4M | 286.3M | 51.6M |
| Intangible Assets | 404.1M | 379.7M | 349.5M | 262.4M | 153.4M |
| Long-term Investments | 59M | 54.8M | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 8.3M | 15.5M | 15.4M | 8.5M | 5.6M |
| Total Non-current Assets | 835.9M | 924.1M | 832.9M | 729.6M | 374M |
| Total Assets | 1.32B | 1.2B | 1.15B | 1.03B | 706.6M |
| Account Payables | 29.6M | 28.8M | 25.8M | 32.3M | 30M |
| Short-term Debt | 13M | 14.1M | 0 | 0 | 6.9M |
| Tax Payables | 4M | 4.8M | 4.6M | 5.1M | 0 |
| Deferred Revenue | 5.2M | 600K | 0 | 0 | 0 |
| Other Current Liabilities | 126.9M | 64.9M | 38.2M | 64.9M | 96.9M |
| Total Current Liabilities | 204.3M | 137.2M | 155.9M | 164.1M | 133.8M |
| Long-term Debt | 79.3M | 130.9M | 38.5M | 39.6M | 202.9M |
| Deferred Tax Liabilities | 35.8M | 3.5M | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 33.5M | 41.3M | 71.5M | 34.9M | 1.9M |
| Total Non-current Liabilities | 148.6M | 175.7M | 207.4M | 162.4M | 204.8M |
| Total Liabilities | 352.9M | 312.9M | 363.3M | 326.5M | 338.6M |
| Common Stock | 800K | 800K | 900K | 900K | 900K |
| Retained Earnings | (254.2M) | (366.2M) | (629.5M) | (756.8M) | (1.12B) |
| Accumulated OCI | (5.1M) | (8.9M) | (3.7M) | (800K) | 800K |
| Other Stockholders Equity | 1.23B | 1.26B | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 967.8M | 885.8M | 783.2M | 701.1M | 368M |
| Total Debt | 92.3M | 145M | 152.1M | 140.3M | 209.8M |
| Net Debt | (166.1M) | 88.1M | 20M | 37.9M | 60.2M |
Myriad Genetics, Inc.
NASDAQ:MYGN
Intrinsic Alpha fair value
Locked
Current Price
$5.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.